proxyvotesnow.com

Home › Companies › ARCUTIS BIOTHERAPEUTICS INC. › 2023-2024

ARCUTIS BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARCUTIS BIOTHERAPEUTICS INC.’s Form 8-K, filed 2024-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Reported items
  • 163Asset managers
  • 894Fund votes
  • 2024-06-14Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARCUTIS BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARCUTIS BIOTHERAPEUTICS INC.

These tallies are ARCUTIS BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARCUTIS BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-14
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Terrie Curran 77,210,679---- 6,467,28012,428,038 Majority: yes
Elect Director: Halley Gilbert 75,828,706---- 7,849,25312,428,038 Majority: yes
Elect Director: Keith R. Leonard, Jr. 59,273,804---- 24,404,15512,428,038 Majority: yes
Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: 56,906,21526,716,60255,142 --12,428,038 Majority: yes

Source: ARCUTIS BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-18 — read the filing on EDGAR.

How asset managers voted at the ARCUTIS BIOTHERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 163 asset managers that disclosed a ARCUTIS BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARCUTIS BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%AGAINST 32%
FOR: 56,906,215AGAINST: 26,716,602

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers:”): 56,906,215 for, 26,716,602 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 115,505,437 outstanding shares: 49.3% for, 23% against (72% of the company cast a for/against vote).

The 162 asset managers below cast 64% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 64%AGAINST 36%
FOR: 63.7%AGAINST: 36.3%NOT VOTED: 0.0%
Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
State Street12,419,09121,512 00For
JENNISON ASSOCIATES LLC10,610,81425,911 00For
SUVRETTA CAPITAL MANAGEMENT, LLC7,361,2850 00For
Prudential/PGIM6,931,0178,775 00For
Polar Capital Holdings Plc6,821,7160 00For
Rubric Capital Management LP5,312,5030 00For
Vanguard05,172,264 00Against
FRANKLIN ADVISERS INC04,432,314 00Against
BlackRock34,2093,826,414 00Against
Cormorant Asset Management, LP2,238,2180 00For
American Century01,967,080 00Against
Bain Capital Life Sciences Investors, LLC1,532,2370 00For
FRANKLIN STRATEGIC SERIES01,525,545 00Against
Charles Schwab01,503,812 00Against
JPMorgan01,458,481 00Against
GW&K Investment Management, LLC8,2291,348,299 00Against
FARALLON CAPITAL MANAGEMENT LLC01,185,577 00Against
Citadel778,9810 00For
J. Goldman & Co LP772,1860 00For
PERCEPTIVE ADVISORS LLC736,3260 00For
T. Rowe Price0679,227 00Against
Direxion Shares ETF Trust0636,400 00Against
Rafferty Asset Management, LLC0636,400 00Against
BALYASNY ASSET MANAGEMENT L.P.0627,676 00Against
HSBC0559,330 00Against

Showing the 25 largest of 162 asset managers. See all 162 in the interactive database.

2. Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Halley E. Gilbert

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 75,828,706WITHHELD: 7,849,253

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Halley Gilbert”): 75,828,706 for, 7,849,253 withheld, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 115,505,437 outstanding shares: 66% for, 7% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (20,486,006 for, 0 against).

FOR 77%ABSTAIN 23%
FOR: 20,486,006 (77.4%)ABSTAIN: 5,985,660 (22.6%)
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street13,9650 5,646,0930Abstain
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century967,8950 00For
Charles Schwab751,9060 00For
Direxion Shares ETF Trust636,4000 00For
JPMorgan527,1900 00For
Fidelity311,2280 44,2770For
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock238,6550 00For
Federated Hermes237,2360 00For
Equitable124,8000 74,7000For
Lincoln Financial125,9110 63,1000For
Aberdeen148,8740 00For
ProShares141,0670 00For
Voya00 136,8930Abstain
SEI124,6100 00For
Invesco96,7340 00For
QUANTITATIVE MASTER SERIES LLC50,0430 00For
AIG/SunAmerica38,9760 00For
Brighthouse36,7050 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Keith R. Leonard, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD 29%
FOR: 59,273,804WITHHELD: 24,404,155

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Keith R. Leonard, Jr.”): 59,273,804 for, 24,404,155 withheld, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 115,505,437 outstanding shares: 51.3% for, 21% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (12,952,748 for, 0 against).

FOR 48.9%ABSTAIN 51.1%
FOR: 12,952,748 (48.9%)ABSTAIN: 13,518,918 (51.1%)
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,652,0860 7,9720For
Vanguard00 5,008,2360Abstain
BlackRock00 2,105,3050Abstain
FRANKLIN STRATEGIC SERIES00 1,525,5450Abstain
American Century00 967,8950Abstain
Charles Schwab00 751,9060Abstain
Direxion Shares ETF Trust00 636,4000Abstain
JPMorgan00 527,1900Abstain
Fidelity00 355,5050Abstain
AMG FUNDS310,9810 00For
T. Rowe Price00 278,2210Abstain
TIAA239,4970 00For
John Hancock198,7110 39,9440For
Federated Hermes00 237,2360Abstain
Equitable00 199,5000Abstain
Lincoln Financial63,1000 125,9110Abstain
Aberdeen00 148,8740Abstain
ProShares00 141,0670Abstain
Voya136,8930 00For
SEI00 124,6100Abstain
Invesco96,7340 00For
QUANTITATIVE MASTER SERIES LLC00 50,0430Abstain
AIG/SunAmerica00 38,9760Abstain
Brighthouse00 36,7050Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Terrie Curran

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 77,210,679WITHHELD: 6,467,280

ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Terrie Curran”): 77,210,679 for, 6,467,280 withheld, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 115,505,437 outstanding shares: 67% for, 6% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (23,980,412 for, 0 against).

FOR 91%9%
FOR: 23,980,412 (90.6%)ABSTAIN: 2,491,254 (9.4%)
Largest asset managers voting on “Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their succ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,652,0860 7,9720For
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century00 967,8950Abstain
Charles Schwab751,9060 00For
Direxion Shares ETF Trust00 636,4000Abstain
JPMorgan527,1900 00For
Fidelity311,2280 44,2770For
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock208,0110 30,6440For
Federated Hermes237,2360 00For
Equitable124,8000 74,7000For
Lincoln Financial151,6350 37,3760For
Aberdeen00 148,8740Abstain
ProShares00 141,0670Abstain
Voya00 136,8930Abstain
SEI124,6100 00For
Invesco00 96,7340Abstain
QUANTITATIVE MASTER SERIES LLC50,0430 00For
AIG/SunAmerica00 38,9760Abstain
Brighthouse00 36,7050Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 49 asset managers below cast 100% of the shares they voted on this item FOR (26,471,666 for, 0 against).

FOR: 26,471,666 (100.0%)
Largest asset managers voting on “TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS ” at ARCUTIS BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Prudential/PGIM6,221,0170 00For
State Street5,660,0580 00For
Vanguard5,008,2360 00For
BlackRock2,105,3050 00For
FRANKLIN STRATEGIC SERIES1,525,5450 00For
American Century967,8950 00For
Charles Schwab751,9060 00For
Direxion Shares ETF Trust636,4000 00For
JPMorgan527,1900 00For
Fidelity355,5050 00For
AMG FUNDS310,9810 00For
T. Rowe Price278,2210 00For
TIAA239,4970 00For
John Hancock238,6550 00For
Federated Hermes237,2360 00For
Equitable199,5000 00For
Lincoln Financial189,0110 00For
Aberdeen148,8740 00For
ProShares141,0670 00For
Voya136,8930 00For
SEI124,6100 00For
Invesco96,7340 00For
QUANTITATIVE MASTER SERIES LLC50,0430 00For
AIG/SunAmerica38,9760 00For
Brighthouse36,7050 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Largest ARCUTIS BIOTHERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of ARCUTIS BIOTHERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 115,505,437 shares outstanding at the time of that meeting.

Top ARCUTIS BIOTHERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1State Street 10.77%
2JENNISON ASSOCIATES LLC 9.21%
3SUVRETTA CAPITAL MANAGEMENT, LLC 6.37%
4Prudential/PGIM 6.01%
5Polar Capital Holdings Plc 5.91%
6Rubric Capital Management LP 4.60%
7Vanguard 4.48%
8FRANKLIN ADVISERS INC 3.84%
9BlackRock 3.34%
10Cormorant Asset Management, LP 1.94%

Reported ARCUTIS BIOTHERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ARCUTIS BIOTHERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Jennison Associates LLC 10.50% DEF14A
Prudential Financial, Inc. 8.56% DEF14A
S 8.25% 13G
Suvretta Capital Management, LLC 8.25% DEF14A
Patrick J. Heron 7.61% DEF14A
Frazier Life Sciences VIII, L.P. 7.61% 13D
State Street 7.60% 13F
BlackRock 7.42% 13F
Vanguard Group 6.19% 13F
Ruberic Capital Management 5.75% DEF14A

Percentages above are of 115,505,437 shares outstanding, as reported by ARCUTIS BIOTHERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUTIS BIOTHERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ARCUTIS BIOTHERAPEUTICS INC.'s shareholder meeting held 2024-06-14, in the 2023-2024 proxy season, 163 asset managers reported how they voted in their SEC Form N-PX filings, covering 894 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUTIS BIOTHERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-18.

ARCUTIS BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.